Summary
This 8-K filing by Pfizer Inc. (PFE) on July 22, 2009, primarily serves to formally incorporate by reference the company's press release detailing its second-quarter 2009 financial results. While the 8-K itself does not contain the detailed financial figures, it signals to investors that these results have been officially disclosed and are available for review. The press release, attached as Exhibit 99, would contain crucial information regarding Pfizer's performance during the quarter, including revenue, earnings, and any significant operational updates that impacted financial outcomes.
Key Highlights
- 1Pfizer Inc. (PFE) filed an 8-K report on July 22, 2009.
- 2The filing's primary purpose is to announce the company's second-quarter 2009 financial results.
- 3The detailed financial results are contained in a press release attached as Exhibit 99.
- 4This press release is officially incorporated by reference into the 8-K filing.
- 5Investors can access the Q2 2009 financial performance details through the referenced press release.
- 6The filing indicates adherence to SEC disclosure requirements for material events like quarterly earnings.
Frequently Asked Questions
Pfizer's Q2 2009 financial results are detailed in a press release dated July 22, 2009, which is attached as Exhibit 99 to this 8-K filing and is incorporated by reference.
No, this 8-K filing does not contain the specific financial numbers itself. It serves to formally reference and include the press release that contains the detailed Q2 2009 financial results.
Exhibit 99 is the press release from Pfizer dated July 22, 2009, which contains the company's Q2 2009 financial results. Its inclusion and incorporation by reference make the disclosed information officially part of the SEC filing.